Resource Summary Report

Generated by RRID on Aug 31, 2026

JJN-3

RRID:CVCL_2078
Type: Cell Line

Proper Citation

RRID:CVCL_2078

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2078

Proper Citation: RRID:CVCL_2078

Description: Cell line JJN-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: PMID:1373872, PMID:1943229, PMID:8943038, PMID:10087940, PMID:10557056, PMID:10583232, PMID:10936422, PMID:11154231, PMID:11157491, PMID:11429052, PMID:16956823, PMID:17171682, PMID:17692805, PMID:18647998, PMID:18700954, PMID:19306352, PMID:21173094, PMID:22806891, PMID:25485619, PMID:25688540, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30285677, PMID:30545397, PMID:30894373, PMID:31068700, PMID:32123307, PMID:35839778

Comments: Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine., Characteristics: IL6 independent., Characteristics: Produces IgA1 kappa., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: JJN-3

Synonyms: JJN3

Cross References: CLO:CLO_0037173, EFO:EFO_0006605, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-1088, BioSample:SAMN03472931, BioSample:SAMN10988455, cancercelllines:CVCL_2078, Cell_Model_Passport:SIDM01036, ChEMBL-Cells:CHEMBL4295422, ChEMBL-Targets:CHEMBL4296444, Cosmic:720788, Cosmic:742956, Cosmic:888017, Cosmic:1483076, Cosmic:1889516, Cosmic:2081385, Cosmic:2131563, Cosmic:2302418, Cosmic:2367283, Cosmic:2391793, Cosmic:2809765, Cosmic-CLP:1327766, DepMap:ACH-000653, DSMZ:ACC-541, DSMZCellDive:ACC-541, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002414, GDSC:1327766, GEO:GSM143339, GEO:GSM290291, GEO:GSM1374579, GEO:GSM1669961, IARC_TP53:30088, LiGeA:CCLE_598, LINCS_LDP:LCL-2052, PharmacoDB:JJN3_706_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_2078, Wikidata:Q54898954

ID: CVCL_2078

Hierarchy: cvcl_l066

Record Creation Time: 20220427T220650+0000

Record Last Update: 20260829T234347+0000

Ratings and Alerts

No rating or validation information has been found for JJN-3.

No alerts have been found for JJN-3.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Burnham CM, et al. (2026) An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. The Journal of biological chemistry, 302(4), 111302.

Fulciniti M, et al. (2026) ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. Blood cancer discovery, 7(1), 129.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany), 104(1), 45.

Gu H, et al. (2026) FAP?+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(18), e06239.

Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. Molecular cell, 85(13), 2597.

Cardona-Benavides IJ, et al. (2025) Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. Molecular oncology.

Burnham CM, et al. (2025) An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. bioRxiv : the preprint server for biology.

Anloague A, et al. (2025) A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma. Haematologica, 110(4), 952.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Barton BE, et al. (2024) Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma. Biomolecules, 14(6).

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Heredia-Guerrero SC, et al. (2024) Functional Investigation of IGF1R Mutations in Multiple Myeloma. Cancers, 16(11).

Rodríguez-García A, et al. (2024) Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(4), 904.

Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. Research square.

Füchsl F, et al. (2024) High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. Nature communications, 15(1), 10520.

Welters C, et al. (2022) Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma. Cancer immunology research, 10(11), 1407.

Aass KR, et al. (2022) Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells. iScience, 25(1), 103605.

Sabol HM, et al. (2022) Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia (New York, N.Y.), 28, 100785.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular cell, 81(10), 2094.